Clene Nanomedicine Inc., a wholly owned subsidiary of Salt Lake City-based Clene Inc., has received a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health.
Received in collaboration Columbia University and Chicago-based Synapticure, the award is for the development of an Expanded Access Protocol (EAP) for the company’s investigational drug, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). An EAP is also referred to as “compassionate use” and is an FDA-regulated pathway that allows people with a serious and life-threatening Please log in to see the rest of this story.
